Biodexa PharmaceuticalsBDRX
13F holders, Q4 2024 (December 31)4holders
$4.05avg. 13F price*
At the end of Q4 2024, 4 institutions reported holding Biodexa Pharmaceuticals PLC (BDRX) in their 13F filings. The largest holders were UBS Group AG ($29K), Rhumbline Advisers ($628) and Contravisory Investment Management, Inc. ($162).
- Company
- Biodexa Pharmaceuticals PLC
- CUSIP
- 59564R807
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $29K |
| Exits | 0 | $0 |
Ownership 4 holders
| UBS Group AG | 0.00% | New | 7,047 | $29K |
| Rhumbline Advisers | 0.00% | New | 154 | $628 |
| Contravisory Investment Management, Inc. | 0.00% | New | 40 | $162 |
| SBI Securities Co., Ltd. | 0.00% | — | 1 | $4 |
"% of holder's portfolio" is BDRX's weight in each manager's 13F, not the share of Biodexa Pharmaceuticals PLC the manager owns.